Several biotech stocks reached 52-week highs on August 12, 2026, driven by positive clinical trial results and quarterly earnings. BioVie surged over 22% to $3.79 after its lead drug candidate Bezisterim met the primary endpoint in a Phase 2 Parkinson's disease trial. Xencor rose over 4% to $23.34, reporting second-quarter revenue of $51.22 million and receiving a $10 million milestone payment from Zenas BioPharma. Alto Neuroscience climbed to $29.70 despite a wider quarterly loss, while Haemonetics reached $91.39 after posting a 5.6% revenue increase to $339 million. ACADIA Pharmaceuticals hit $29.85, reporting a profit of $32 million and projecting full-year 2026 revenues between $1.24 billion and $1.30 billion.
